Developing an immune signature for triple-negative breast cancer to predict prognosis and immune checkpoint inhibitor response.
Future Oncol
; 18(9): 1055-1066, 2022 Mar.
Article
en En
| MEDLINE
| ID: mdl-35105171
ABSTRACT
Aim:
We aimed to develop a new signature based on immune-related genes to predict prognosis and response to immune checkpoint inhibitors in patients with triple-negative breast cancer (TNBC). Materials &methods:
Single-sample gene set enrichment was used to develop an immune-based prognostic signature (IPRS) for TNBC patients. We conducted multivariate Cox analysis to evaluate the prognosis value of the IPRS.Result:
An IPRS based on 66 prognostic genes was developed. Multivariate Cox analysis indicated that the IPRS was an independent factor for prognosis. PD-1, PD-L1, PD-L2 and CTLA4 gene expression was higher in the low-risk group, suggesting IPRS could predict the response to immune checkpoint inhibitors.Conclusion:
The IPRS might be a reliable signature to predict TNBC patients' prognosis and response to immune checkpoint inhibitors, but needs prospective validation.Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Pronóstico
/
Regulación Neoplásica de la Expresión Génica
/
Neoplasias de la Mama Triple Negativas
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Evaluation_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
China